Literature DB >> 30183903

[Pathology of heart transplantation in peru: experience with 61 cases in a national reference center].

Cristian Aguilar1, Walter Alarco2, Franz Soplopuco3, Julio Morón3, Miguel Lescano2, Jorge Morales4, David Galvez2.   

Abstract

OBJETIVE.: To describe the histopathological characteristics of explanted hearts and post-transplant biopsy specimens at a national reference center in Peru. MATERIALS AND METHODS.: A case series study of patients who underwent heart transplantation between March 2010 and February 2018. RESULTS.: Sixty-one (61) transplanted patients with a mean age of 40.1 years (range: 9-66 years). Five cases (8.2%) initially diagnosed as dilated cardiomyopathy were reclassified after the histopathological study. The three leading causes of primary disease after transplantation were: idiopathic dilated cardiomyopathy (50.8%), ischemic cardiomyopathy (16.4%), and valvular cardiomyopathy (6.6%). The mean follow-up was 2.8 years. The post-transplant survival rate was 85.1% at 1 year and 82.8% at 5 years. Moderate/severe acute cellular rejection occurred in 12 patients (21.1%) and antibody-mediated rejection occurred in 3 patients (5.3%). CONCLUSIONS.: Routine histopathological evaluation of the explanted heart is essential to confirm the etiology of heart failure, especially in cases clinically diagnosed as dilated cardiomyopathy. In addition, routine follow-up through endomyocardial biopsies shows that acute cellular rejection is still a frequent complication after a heart transplant, especially within the first year, and that antibody-mediated rejection has a low incidence in our population.

Entities:  

Mesh:

Year:  2018        PMID: 30183903     DOI: 10.17843/rpmesp.2018.352.3264

Source DB:  PubMed          Journal:  Rev Peru Med Exp Salud Publica        ISSN: 1726-4634


  1 in total

1.  Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV).

Authors:  Manuel Chacón-Diaz; Rocío Laymito Quispe; Akram Hernández-Vásquez; Rodrigo Vargas-Fernández
Journal:  Front Cardiovasc Med       Date:  2022-05-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.